The Role of Ruxolitinib in Myeloproliferative Neoplasms
Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.
Jorge E. Cortes, MD, director, Georgia Cancer Center, Augusta University, explains how ruxolitinib (Jakafi) is used to treat various myeloproliferative neoplasms and which patients require other therapies.
Ruxolitinib is very effective in myelofibrosis, particularly for patients who have a large spleen size or are symptomatic. Since ruxolitinib does not cure the disease, patients without these issues do not have the same benefit.
Ruxolitinib is also approved for the treatment of polycythemia vera and essential thrombocythemia for patients who have not responded to initial therapy and for whom few options are available.
<< View more from the 24th Annual International Congress on Hematologic Malignancies
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
